Huafeng Wang on Muck Rack

Huafeng Wang

  • Editor in Chief, China CIO News
As seen in: Nature, Wiley Online Library, MDPI, ACS Publications, Science Magazine, Cell Reports, The Lancet, The Journal of Immunology, Archives of Pathology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Huafeng

Contact Huafeng, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Executive green cognition, risk preference, and ESG greenwashing

|
By Guangrui Liu, Yujie Lin, Huafeng Wang, Zhuoran Liu
| Nature Verified
Abstract Executives with high levels of green cognition play key roles in enterprises in terms of choosing green development and fundamentally guaranteeing the sustainable development of China’s real economy. On the basis of risk aversion theory, the relationships among executives’ green cognition level, risk preferences and environmental, social, and governance (ESG) greenwashing are examined.
Open in Who Shared Issue with article?

Diagnostic value of bone marrow smear for amyloid detection and its correlation with clinical features in systemic light-chain amyloidosis

|
By Jianhu Li, Qiusu Tang, Mengmeng Tang, Huafeng Wang, Shuqi Zhao, Xiangli Gao, Dan Shen, Ting Zhang, Yijing Zhu, Jixiang Tong, Yingqing Xu, Hongyan Tong, Jie Jin, Min Yang, Zhijuan Chang, Shuchong Yuan
| Nature Verified
Abstract This study aimed to evaluate the diagnostic value of bone marrow smear in systemic light chain (AL) amyloidosis and to investigate the correlation between bone marrow amyloid deposition and clinical characteristics. A total of 252 patients with AL amyloidosis were enrolled, including 126 with positive bone marrow biopsies and 126 with negative biopsies. Bone marrow smear detected amyloid deposits in 121 of 252 patients (48.0%).
Open in Who Shared Issue with article?

Efficacy and safety of short-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia

|
By Ge Liu, Yile Zhou, Yinjun Lou, Liping Mao, Qian Wang, Hongfei Wu, Hongyan Tong, Xudong Wei, Jie Jin, Huafeng Wang, Qingsong Yin
| Nature Verified
To the Editor Blinatumomab has significantly improved survival in patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) [1,2,3], particularly those with measurable residual disease (MRD) positivity [4]. Recently, it has been integrated into first-line therapy of B-ALL patients [5,6,7].
Open in Who Shared Issue with article?
See all 25 licensed articles (26 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified